Qiagen Monopoly In HPV Test Market Won’t Last, Judge Says
This article was originally published in The Gray Sheet
Executive Summary
A U.S. district court turned down Third Wave Technologies' claims that Qiagen engages in anti-competitive behavior in the cervical cancer screening space, but the ruling suggests the direction of the market will be in Third Wave's favor